TY - JOUR
T1 - Sertraline treatment for generalized anxiety disorder
T2 - A randomized, double-blind, placebo-controlled study
AU - Brawman-Mintzer, Olga
AU - Knapp, Rebecca G.
AU - Rynn, Moira
AU - Carter, Rickey E.
AU - Rickels, Karl
PY - 2006/6
Y1 - 2006/6
N2 - Objective: This study assessed the efficacy and safety of sertraline in the treatment of generalized anxiety disorder (GAD). Method: The study was conducted from April 2000 to May 2002. Outpatients with DSM-IV GAD (N = 326) who satisfied inclusion/exclusion criteria and completed a 1-week screening phase were randomly assigned to 10-week double-blind treatment with flexible dosing of sertraline (50-200 mg/day) or placebo. The primary efficacy measure was change from baseline in Hamilton Rating Scale for Anxiety (HAM-A) total score. Response was defined as a 50% or greater decrease in HAM-A total score at endpoint. Results: Sertraline produced a statistically significant reduction in anxiety symptoms, as measured by HAM-A total change scores (p = .032), HAM-A psychic anxiety subscale (p = .011), and Hospital Anxiety and Depression Scale-anxiety subscale (p = .001). Response rates were significantly higher (p = .05) for the sertraline group (59.2%) compared to the placebo group (48.2%). Sertraline was well tolerated, with only sexual side effects reported significantly more often by subjects receiving sertraline than those receiving placebo. Conclusion: Despite the relatively small between-group differences, study findings suggest a role for sertraline in the acute treatment of GAD.
AB - Objective: This study assessed the efficacy and safety of sertraline in the treatment of generalized anxiety disorder (GAD). Method: The study was conducted from April 2000 to May 2002. Outpatients with DSM-IV GAD (N = 326) who satisfied inclusion/exclusion criteria and completed a 1-week screening phase were randomly assigned to 10-week double-blind treatment with flexible dosing of sertraline (50-200 mg/day) or placebo. The primary efficacy measure was change from baseline in Hamilton Rating Scale for Anxiety (HAM-A) total score. Response was defined as a 50% or greater decrease in HAM-A total score at endpoint. Results: Sertraline produced a statistically significant reduction in anxiety symptoms, as measured by HAM-A total change scores (p = .032), HAM-A psychic anxiety subscale (p = .011), and Hospital Anxiety and Depression Scale-anxiety subscale (p = .001). Response rates were significantly higher (p = .05) for the sertraline group (59.2%) compared to the placebo group (48.2%). Sertraline was well tolerated, with only sexual side effects reported significantly more often by subjects receiving sertraline than those receiving placebo. Conclusion: Despite the relatively small between-group differences, study findings suggest a role for sertraline in the acute treatment of GAD.
UR - http://www.scopus.com/inward/record.url?scp=33745877173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745877173&partnerID=8YFLogxK
U2 - 10.4088/JCP.v67n0603
DO - 10.4088/JCP.v67n0603
M3 - Article
C2 - 16848646
AN - SCOPUS:33745877173
SN - 0160-6689
VL - 67
SP - 874
EP - 881
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
IS - 6
ER -